U.S. Markets closed

Radius (RDUS) Catches Eye: Stock Jumps 6.8%

Zacks Equity Research

Radius Health, Inc. RDUS was a big mover last session, as the company saw its shares rise nearly 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company—as the stock is now up 39.3% in the past one-month time frame.

The company has seen four positive estimate revisions in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few weeks, suggesting that more solid trading could be ahead for Radius. So, make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.

Radius currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

Radius Health, Inc. Price

Radius Health, Inc. Price

Radius Health, Inc. price | Radius Health, Inc. Quote

Investors interested in the Medical - Drugs industry may consider FibroGen, Inc FGEN, which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is RDUS going up? Or down? Predict to see what others think:Up or Down

Legalizing THIS Could Be Even Bigger than Marijuana

Americans spend an estimated $150 billion in this industry every year… more than twice as much as they
spend on marijuana.

Now that 8 states have fully-legalized it (with several more states following close behind), Zacks has
identified 5 stocks that could soar in response to the powerful demand. One industry insider described
the future as “mind-blowing” – and early investors can still get in ahead of the surge.

See these 5 “sin stocks” now >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Radius Health, Inc. (RDUS) : Free Stock Analysis Report
 
FibroGen, Inc (FGEN) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research